Wegovy and Ozempic contain the same active ingredient—semaglutide—but they are approved for different purposes. Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for chronic weight management. The dosing schedules differ, and insurance coverage rules differ. At PEAK, we prescribe Wegovy for weight loss when clinically appropriate, never off-label Ozempic.
Side-by-side comparison
This table outlines the key differences between these two semaglutide formulations.
| Wegovy | Ozempic | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA approval | Chronic weight management (obesity/overweight) | Type 2 diabetes management |
| Max dose | 2.4 mg weekly | 2.0 mg weekly (off-label use at higher doses) |
| Typical titration | 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg | 0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg |
| Pen design | Single-dose pre-filled pen (4 doses per box) | Multi-dose pen (4 or 8 doses per pen) |
| Insurance for weight loss | Covered by many plans (with prior authorization) | Not covered for weight loss; requires diabetes diagnosis |
| Typical cash price | high out-of-pocket pricing | high out-of-pocket pricing |
| Clinical trial focus | STEP trials (weight management) | SUSTAIN trials (diabetes management) |
Note: Both medications are manufactured by Novo Nordisk. Prices reflect list prices without insurance or manufacturer savings programs.
Why they're the same molecule but different medications
Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut naturally produces to regulate appetite and blood sugar. Novo Nordisk, the manufacturer, developed semaglutide initially for type 2 diabetes (Ozempic). During clinical trials, researchers observed significant weight loss as a secondary effect.
This led to a separate FDA approval process specifically for chronic weight management—at higher doses and under the brand name Wegovy. The molecule is identical, but the FDA approval, dosing protocol, and intended patient population are different. For a detailed look at what patients achieve on the weight-loss formulation, see our Wegovy treatment overview.
From a regulatory standpoint, these are two distinct medications. You cannot simply substitute one for the other, even though they share the same active ingredient. Prescribing Ozempic for weight loss in a patient without diabetes is considered off-label use, which most insurance plans will not cover and which raises clinical documentation concerns.
Different FDA approvals mean different coverage
Ozempic is indicated for adults with type 2 diabetes to improve glycemic control. It can be prescribed alongside diet and exercise, and it has cardiovascular benefits in patients with established cardiovascular disease. Weight loss is a known side effect, but it is not the primary therapeutic purpose. For patients with both type 2 diabetes and obesity, our guide on Wegovy and type 2 diabetes explains how these treatment paths intersect.
Wegovy is indicated for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity—such as hypertension, type 2 diabetes, or dyslipidemia. It must be used alongside reduced-calorie diet and increased physical activity.
Insurance companies base coverage decisions on FDA-approved indications. If you have a diabetes diagnosis, your plan may cover Ozempic. If you're seeking treatment for obesity without diabetes, your plan will require Wegovy (if weight loss medications are covered at all). Prescribing Ozempic off-label for weight loss often results in claim denials.
Same molecule. Different use cases. Different insurance rules. The distinction matters.
Insurance coverage: why Wegovy requires prior authorization
Most insurance plans that cover GLP-1 medications for weight loss will cover Wegovy—but they require prior authorization. This means your clinician must submit documentation proving you meet medical necessity criteria: BMI thresholds, documented comorbidities, and evidence of lifestyle modification efforts.
Ozempic, by contrast, is typically covered for patients with type 2 diabetes without prior authorization (though some plans still require it). If you do not have diabetes and your clinician prescribes Ozempic for weight loss, your insurance will likely deny the claim.
Some patients ask whether they can use Ozempic "off-label" and pay cash to avoid insurance complications. This is technically possible, but it creates several issues: (1) the dosing schedule for Ozempic does not go as high as Wegovy's FDA-approved weight loss dose, (2) you lose access to manufacturer savings programs designed for Wegovy, and (3) off-label prescribing may complicate future insurance appeals if you later seek coverage for Wegovy. Patients also often ask about whether a generic version of Wegovy will become available to address cost concerns.
At PEAK, we prescribe the medication that matches your diagnosis and your insurance plan's coverage rules. If you qualify for weight loss treatment, we prescribe Wegovy and handle the prior authorization process. We do not prescribe Ozempic off-label for weight management.
Which one is right for you?
The decision is not really about preference—it's about your diagnosis and your insurance plan's formulary. If you're trying to determine whether either medication is right for your situation, our guide to choosing the right weight loss medication walks through the full clinical decision framework.
You'll likely receive Ozempic if:
You have a diagnosis of type 2 diabetes, and your clinician determines a GLP-1 medication is appropriate for glycemic control. Weight loss may occur as a secondary benefit, but the primary goal is managing your blood sugar.
You'll likely receive Wegovy if:
You meet the BMI criteria for chronic weight management (with or without comorbidities) and do not have diabetes—or you have diabetes but your clinician is prescribing specifically for weight loss. Wegovy is the FDA-approved option for this indication.
What if you have both obesity and diabetes?
This is where clinical judgment matters. Your clinician may prescribe Ozempic to address diabetes (with weight loss as a beneficial side effect) or Wegovy to address obesity (with improved glycemic control as a side effect). The choice depends on which condition is the primary treatment target and which medication your insurance plan covers.
In either case, the medication is the same molecule. What changes is the dose, the approval pathway, and the billing code your clinician uses when submitting to insurance.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
